Product information and disease descriptionProduct descriptionProduct information
Product comparison
33 evidence topics · 30 sources
Lanifibranor: company statement of its position among PPAR agonists
Approved and phase 3 competitors named by Inventiva in its annual report
Lanifibranor with GLP-1 receptor agonists: company presentation of potential synergy
Resmetirom (REZDIFFRA): indication and accelerated approval
Resmetirom: mechanism of action, partial thyroid hormone receptor-beta agonist
Resmetirom: oral once-daily dosing based on body weight
Resmetirom: month 12 histology in Trial 1 (NCT03900429), 888 F2 and F3 participants, missing biopsy counted as nonresponse
| Endpoint at month 12 | Placebo (N=294) | REZDIFFRA 80 mg (N=298) | REZDIFFRA 100 mg (N=296) |
|---|---|---|---|
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist A (%) | “13” | “27” | “36” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “14 (8, 20)” | “23 (16, 30)” |
| Resolution of steatohepatitis and no worsening of liver fibrosis, Pathologist B (%) | “9” | “26” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “17 (11, 23)” | “15 (9, 21)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist A (%) | “15” | “23” | “28” |
| Difference vs. placebo (95% CI), Pathologist A | Not applicable | “8 (2, 14)” | “13 (7, 20)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, Pathologist B (%) | “13” | “23” | “24” |
| Difference vs. placebo (95% CI), Pathologist B | Not applicable | “11 (5, 17)” | “11 (5, 17)” |
Resmetirom: MAESTRO-NASH week 52 primary analysis population of 966 participants
Semaglutide (WEGOVY): MASH indication and accelerated approval
Semaglutide: mechanism of action, GLP-1 receptor agonist
Semaglutide: subcutaneous once-weekly maintenance dosing for MASH
Semaglutide: week 72 histology in Study 11 (NCT04822181), 800 F2 and F3 participants, reference-based multiple imputation
| Endpoint at week 72 | Placebo (N=266) | WEGOVY injection (N=534) | Difference vs. placebo (95% CI) |
|---|---|---|---|
| Resolution of steatohepatitis and no worsening of liver fibrosis, response rate (%) | “34” | “63” | “29 (21, 36)” |
| Improvement in liver fibrosis and no worsening of steatohepatitis, response rate (%) | “22” | “37” | “14 (8, 21)” |
| Resolution of steatohepatitis and improvement in liver fibrosis, response rate (%) | “16” | “33” | “17 (10, 23)” |
Semaglutide: phase 3 part 1 interim analysis at week 72 in the first 800 of 1197 participants
Efruxifermin: acquisition of Akero Therapeutics by Novo Nordisk completed in December 2025
Efruxifermin: phase 3 trial in F2 or F3 MASH (NCT06215716), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Akero Therapeutics, Inc” |
| Status | “Recruiting” |
| Study start (actual) | “2023-12-01” |
| Primary completion (estimated) | “2033-02” |
| Enrollment (estimated) | “1650” |
| Primary outcome, cohort 1 | “Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis” |
| Primary outcome | “Event-free survival” |
Efruxifermin: HARMONY phase 2b week 24 histology, liver biopsy analysis set and full analysis set
“HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2·3 [95% CI 1·1-4·8]; p=0·025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2·2 [1·0-5·0]; p=0·036).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2·2 [95% CI 1·0-4·8]; p=0·033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1·9 [0·8-4·3]; p=0·123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegozafermin: acquisition of 89bio by Roche, agreement in September 2025 and tender offer completed in October 2025
Pegozafermin: ENLIGHTEN-Fibrosis phase 3 trial (NCT06318169), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Hoffmann-La Roche” |
| Status | “Recruiting” |
| Study start (actual) | “2024-03-13” |
| Primary completion (estimated) | “2029-02” |
| Enrollment (estimated) | “1350” |
| Primary outcome | “Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52” |
| Primary outcome | “Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52” |
| Primary outcome | “Time to First Occurrence of Disease Progression” |
Pegozafermin: ENLIVEN phase 2b week 24 histology, full analysis population with multiple imputation
“In this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial, we randomly assigned patients with biopsy-confirmed NASH and stage F2 or F3 (moderate or severe) fibrosis to receive subcutaneous pegozafermin at a dose of 15 mg or 30 mg weekly or 44 mg once every 2 weeks or placebo weekly or every 2 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 222 patients who underwent randomization, 219 received pegozafermin or placebo. The percentage of patients who met the criteria for fibrosis improvement was 7% in the pooled placebo group, 22% in the 15-mg pegozafermin group (difference vs. placebo, 14 percentage points; 95% confidence interval [CI], −9 to 38), 26% in the 30-mg pegozafermin group (difference, 19 percentage points; 95% CI, 5 to 32; P = 0.009), and 27% in the 44-mg pegozafermin group (difference, 20 percentage points; 95% CI, 5 to 35; P = 0.008). The percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs. placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Missing end-point data (for 28 patients) were imputed with the use of multiple imputation by means of logistic regression with all collected outcomes. The full analysis population included all the enrolled patients who had undergone randomization and received at least one dose of pegozafermin or placebo and who had confirmed fibrosis stage F2 or F3 (indicating moderate or severe fibrosis) and a nonalcoholic fatty liver disease activity score of at least 4 at baseline, as assessed on independent review by a three-pathologist panel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efimosfermin alfa (GSK): once-monthly FGF21 analog in phase 3, FDA Breakthrough Therapy and EMA PRIME designations in April 2026
Efimosfermin alfa: ZENITH-1 phase 3 trial in F2 or F3 MASH (NCT07221227), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “GlaxoSmithKline” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-24” |
| Primary completion (estimated) | “2028-03-29” |
| Enrollment (estimated) | “1200” |
| Primary outcome | “Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52” |
| Primary outcome | “Time from randomization to an adjudicated composite liver-related clinical outcome” |
Efimosfermin alfa: phase 2 trial in F2 or F3 MASH with a safety primary endpoint at week 24
“Participants were randomly assigned 1:1 to efimosfermin 300 mg or placebo administered by subcutaneous injection every 4 weeks (Q4W) over 24 weeks, stratified by MASH fibrosis stage (F2 vs F3 stage).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was safety and tolerability (ie, treatment-emergent adverse events, changes from baseline to week 24 in blood pressure and heart rate, and the incidence of grade 3 and grade 4 laboratory abnormalities at week 24), analysed in all participants who received at least one dose.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between May 4, 2023, and March 22, 2024, of 1171 participants screened, 84 participants were randomly assigned to efimosfermin 300 mg Q4W (n=43) or placebo (n=41)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events were reported in 29 (67%) of 43 participants receiving efimosfermin and 22 (55%) of 40 receiving placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survodutide: LIVERAGE phase 3 trial in noncirrhotic F2 to F3 MASH (NCT06632444), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Boehringer Ingelheim” |
| Status | “Recruiting” |
| Study start (actual) | “2024-10-14” |
| Primary completion (estimated) | “2031-12-27” |
| Enrollment (estimated) | “1800” |
| Primary outcome, part 1 | “Part 1: Resolution of MASH without worsening of liver fibrosis on MASH Clinical Research Network (CRN) fibrosis score” |
| Primary outcome, part 1 | “Part 1: At least a 1-point improvement in fibrosis stage with no worsening of MASH” |
Survodutide: phase 2 week 48 histology in F1 to F3 MASH, 293 participants who received at least one dose
“In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: SYNERGY-Outcomes phase 3 master protocol in high-risk MASLD selected by noninvasive tests (NCT07165028), registry record
| Field | Quoted record |
|---|---|
| Sponsor | “Eli Lilly and Company” |
| Status | “Recruiting” |
| Study start (actual) | “2025-10-15” |
| Primary completion (estimated) | “2030-08” |
| Enrollment (estimated) | “4500” |
| Primary outcome | “Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)” |
Tirzepatide: SYNERGY-NASH phase 2 week 52 histology in F2 or F3 MASH, 190 randomized with missing biopsies imputed
“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pemvidutide: PERFORMA phase 3 trial in F2 to F3 MASH initiated in August 2026
| Field | Quoted record |
|---|---|
| Sponsor | “Altimmune, Inc.” |
| Status | “Recruiting” |
| Study start (actual) | “2026-07-30” |
| Primary completion (estimated) | “2028-12” |
| Enrollment (estimated) | “1800” |
| Arms | “Pemvidutide 1.8 mg” |
| Arms | “Pemvidutide 2.4 mg” |
Pemvidutide: IMPACT phase 2b week 24 histology in F2 or F3 MASH, intention-to-treat population
“IMPACT is an ongoing 48-week international, randomised, double-blind, placebo-controlled, phase 2b trial in patients with biopsy-confirmed MASH and fibrosis stage F2 or F3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The dual primary endpoints were MASH resolution without worsening of fibrosis or at least one stage liver fibrosis improvement without worsening of MASH at 24 weeks in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the 1·2 mg pemvidutide group (difference of 38% [95% CI 21-56]; p<0·0001), and 45 (52%) of 85 patients in the 1·8 mg pemvidutide group (difference of 32% [95% CI 19-46]; p<0·0001). Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the 1·2 mg pemvidutide group (difference of 5% [95% CI -13 to 22]; p=0·59), and 30 (36%) of 85 patients in the 1·8 mg pemvidutide group (difference of 8% [95% CI -6 to 22]; p=0·27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MASH at this timepoint.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Denifanstat: phase 3 FASCINATE-3 trial withdrawn and further MASH development deferred pending non-dilutive financing
| Field | Quoted record |
|---|---|
| Sponsor | “Sagimet Biosciences Inc.” |
| Status | “Withdrawn” |
| Why stopped | “Business decision” |
| Enrollment (actual) | “0” |
Denifanstat: FASCINATE-2 phase 2b week 52 histology in F2 or F3 MASH, intention-to-treat population
“participants aged 18 years and older with biopsy-confirmed MASH and stage F2 or F3 fibrosis were randomly assigned (2:1) to receive either 50 mg oral denifanstat or placebo once per day for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the ITT population, 42 (38%) of 112 participants in the denifanstat group had a 2-point or greater improvement in NAS without a worsening of fibrosis versus nine (16%) of 56 participants in the placebo group (common risk difference 21·0%, 95% CI 8·1-33·9; p=0·0035). 29 (26%) of 112 participants in the denifanstat group showed MASH resolution with a 2-point or greater improvement in NAS without a worsening of fibrosis compared with six (11%) of 56 participants in the placebo group (common risk difference 13·0%, 0·7-25·3; p=0·0173).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparison of histologic response: company presentation, with its caveat that results may not be comparable
Cross-trial comparison of adiponectin change: lanifibranor, resmetirom, efruxifermin, and pegozafermin, with the authors’ caveat that results may not be comparable
| Product (trial, time point) | Dose | Absolute change in adiponectin from baseline at end of treatment, µg/ml |
|---|---|---|
| Lanifibranor (NATIVE, 24 weeks) | “800mg” | “+ 11.95 (8.97 to14.94)” |
| Lanifibranor (NATIVE, 24 weeks) | “1200mg” | “+ 17.12 (14.29 to 19.96)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “80mg” | “+ 0.86 (0.19)” |
| Resmetirom (MAESTRO-NASH, 52 weeks) | “100mg” | “+ 1.1 (0.19)” |
| Efruxifermin (HARMONY, 24 weeks) | “28mg” | “+ 1.4(0.74 to 2.08)” |
| Efruxifermin (HARMONY, 24 weeks) | “50mg” | “+ 3.0(2.34 to 3.71)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “15mg” | “+ 1.1(0.7)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “30mg” | “+ 1.1(0.3)” |
| Pegozafermin (ENLIVEN, 24 weeks) | “44mg” | “+ 1.2 (0.4)” |
Network meta-analysis of 29 randomized trials including lanifibranor, with the authors’ stated limitations
“We searched PubMed and Embase databases from January 1, 2020 to December 1, 2024, for published randomized controlled trials comparing pharmacological interventions in patients with biopsy-proven MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 29 randomized controlled trials (n=9324) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from eligible studies were extracted as intention-to-treat (ITT) analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegozafermin (RR: 3.46, CrI: 1.54–11.15), cilofexor + firsocostat (RR: 2.67, CrI: 1.05–8.13), denifanstat (RR: 1.94, CrI: 1.04–4.04), survodutide (RR: 1.86, CrI: 1.18– 3.28), obeticholic acid (RR: 1.85, CrI: 1.30–2.75), tirzepatide (RR: 1.77, CrI: 1.17–2.94), resmetirom (RR: 1.64, CrI: 1.27–2.20), and semaglutide (RR: 1.51, CrI: 1.23–1.90) were statistically better than placebo in achieving ≥1 stage of fibrosis improvement without worsening MASH (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pegozafermin (RR: 8.65, CrI: 2.63–59.42), survodutide (RR: 6.62, CrI: 3.13–17.97), tirzepatide (RR: 4.65, CrI: 2.31–10.66), efruxifermin (RR: 3.51, CrI: 1.83–8.17), liraglutide (RR: 3.23, CrI: 1.11–14.17), vitamin E + pioglitazone (RR: 3.03, CrI: 1.31–9.04), resmetirom (RR: 2.54, CrI: 1.86–3.55), pioglitazone (RR: 2.29, CrI: 1.41–4.03), denifanstat (RR: 2.03, CrI: 1.04–4.72), semaglutide (RR: 1.87, CrI: 1.60–2.24), and lanifibranor (RR: 1.93, CrI: 1.30–3.02) were statistically better than placebo in achieving MASH resolution without worsening fibrosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, we acknowledge the modest number of trials with direct comparisons between pharmacological therapies, and the small number of trials for each agent; hence, most comparisons between treatments were based on indirect evidence; head-to-head trials versus other drugs should be considered to validate our findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparability between trials was further limited by their heterogeneity in design and population (eg, demographics and comorbidities).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | SUCRA, fibrosis improvement ≥1 stage without worsening MASH |
|---|---|
| Pegozafermin | “79.92”View highlighted excerpt for this quote |
| Denifanstat | “60.64”View highlighted excerpt for this quote |
| Survodutide | “59.89”View highlighted excerpt for this quote |
| Tirzepatide | “57.37”View highlighted excerpt for this quote |
| Efruxifermin | “56.20”View highlighted excerpt for this quote |
| Resmetirom | “50.14”View highlighted excerpt for this quote |
| Semaglutide | “47.04”View highlighted excerpt for this quote |
| Lanifibranor | “46.56”View highlighted excerpt for this quote |